Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] with a [[Biomarkers#FLT3|FLT3]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. | + | *11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] with a [[Biomarkers#FLT3|FLT3]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. ''(Based on ADMIRAL)'' |
== Patient Drug Information== | == Patient Drug Information== | ||
Revision as of 21:39, 29 April 2021
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)
Patient Drug Information
Also known as
- Code name: ASP2215
- Brand name: Xospata